araag2/HINT huggingface dataset:
Clinical trial NCT02061631 (phase 2, status: completed)
Conditions: squamous cell carcinoma of head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cisplatin, docetaxel xrp6976, dexamethasone, dexamethasone
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion criteria :

          -  Histologically confirmed, unresectable locally advanced squamous cell carcinoma of
             head and neck of oral cavity in stage III-IV without evidence of distant metastases.

          -  No prior chemotherapy or radiation therapy.

          -  Having at least one measurable lesion in one dimension.

          -  Age ≥18 and <65 years with Eastern Cooperative Oncology Group ≤ 1.

          -  Adequate organ function:

          -  Adequate hematological function

          -  Adequate hepatic function

          -  Renal function within normal limits

        Exclusion criteria:

          -  Peripheral neuropathy > grade 1 or other serious diseases (unstable ischaemic heart
             disease, acute myocardial infarction six months prior to inclusion, history of
             significant neurological or psychiatric disorder or active peptic ulcer).

          -  Being treated concomitantly with corticosteroids (except as pre-medication).

          -  Patients having another type of cancer.

          -  Previous chemotherapy or radiotherapy.

          -  Any previous definitive surgery for squamous cell carcinoma of head and neck.

          -  Severe weight loss (> 20 % of body weight) in the preceding 3 months.

          -  Hearing loss (> grade 2).

          -  Pregnancy (pregnancy test result for women of childbearing potential).

          -  Sexually active females with lack of adequate contraception.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT02063295 (phase 2, status: completed)
Conditions: obesity, over-weight, hypothalamic injury, craniopharyngioma
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: zgn-440 sterile diluent, zgn-440 for injectable suspension
SMILES: CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by
             BMI ≥30 and ≤60 kg/m2

          -  Greater than 6 months post-treatment, including chemotherapy, surgery or radiation
             with resulting injury to the hypothalamus and/or the pituitary

          -  Stable body weight for at least 3 months

          -  Type 2 diabetes mellitus is allowed

        Exclusion Criteria:

          -  Males taking gonadotropin replacement therapy (LH/FSH)

          -  Subjects who are planning any fertility treatment within 6 months of study
             participation

          -  Use of weight loss agents, including herbal medications, in the past 3 months

          -  Current or anticipated chronic use of narcotics or opiates

          -  History of severe psychiatric disorders

          -  Type 1 diabetes mellitus

          -  Metabolic disorders or genetic disorders linked to obesity

          -  History of any bariatric surgery

          -  Participation in any clinical study with an investigational drug or device within the
             3 months prior to enrollment in this study

          -  Blood loss or donation >500 mL within the past 3 months

          -  Females who are pregnant, nursing, intend to become pregnant during the study or any
             males who plan to father/conceive a child within 6 months after completion of study
             participation
Clinical trial NCT02063854 (phase 2/phase 3, status: completed)
Conditions: involutional osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: ne-58095 ir, ne-58095 ir placebo, ne-58095 dr, ne-58095 dr placebo
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with a diagnosis of involutional osteoporosis

          2. Male or female outpatients (including patients admitted to the hospital for tests)
             aged ≥ 50 years at the time of consent

          3. Women for whom at least 2 years have passed since the last natural menstruation

        Exclusion Criteria:

          1. Patients with secondary osteoporosis

          2. Patients with diseases (other than secondary osteoporosis) that present with decreased
             bone mass

          3. Patients with findings that affects the measurement of mean bone mineral density of
             the lumbar spine by dual-energy X-ray absorptiometry (DXA)

          4. Patients with a history of radiotherapy to the lumbar spine or the pelvis

          5. Patients who are planning to receive surgical dental procedures such as tooth
             extraction (including dental implant treatment) during the treatment period

          6. Patients with a history of treatment with any anti-receptor activator of nuclear
             factor-κB ligand (RANKL) monoclonal antibodies or parathyroid hormone products within
             1 year before the start of the treatment period

          7. Patients with a history of treatment with any bisphosphonate products within 24 weeks
             before the start of the treatment period

          8. Patients who have received any drugs that affect bone metabolism within 8 weeks before
             the start of the treatment period

          9. Patients with disorders such as esophagitis, peptic ulcer (e.g., esophageal ulcer,
             gastric ulcer, and duodenal ulcer), or gastrointestinal bleeding

         10. Patients with disorders that delay esophageal emptying (e.g., dysphagia,
             esophagostenosis, or achalasia of the esophagus)

         11. Patients with hypocalcemia

         12. Patients with hypercalcemia

         13. Patients with a diagnosis of renal calculus

         14. Patients with serious renal, hepatic, or cardiac disease

         15. Patients who have received surgical dental procedures, such as a tooth extraction
             (including dental implant treatment), but whose dental problems remain unresolved at
             the start of the treatment period.
Clinical trial NCT02065349 (phase 2, status: completed)
Conditions: post-herpetic neuralgia (phn), neuropathic pain, painful diabetic peripheral neuropathy (pdpn)
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: asp8477, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  PDPN subject must have:

               -  Established diagnosis of diabetes (type I or II) with painful diabetic peripheral
                  neuropathy and glycosylated hemoglobin (HbA1c) ≤ 11% at Screening.

               -  Stable glycemic control (HbA1c ≤ 11%) achieved by a drug regimen for at least 3
                  months prior to Screening.

               -  At least a 1-year history of DPN pain.

               -  Diabetic distal symmetrical polyneuropathy symptoms (including pain) stable for
                  at least the last 3 months prior to Screening based on PI judgment and
                  subject-reported medical history.

          -  PHN subject must have pain present ≥ 6 months after healing of the herpes zoster rash.

        Exclusion Criteria:

          -  Subject has significant pain of an etiology other than PDPN or PHN, or clearly non
             differentiated pain, or plantar fasciitis, heel spurs, tibial neuropathy, Morton's
             neuroma, bunions, metatarsalgia, arthritis in feet, ischemic pain, neurological
             disorders unrelated to diabetic neuropathy, skin condition in area of neuropathy that
             could alter sensation, malignancy, or current orthostatic hypotension, hypo or
             hypertension, syncope or clinically significant ECG, clinical intolerance to
             Non-steroidal anti-inflammatory drugs (NSAIDs) or ASP8477, depression, psychosis or
             psychiatric or neurological illness, BMI of over 35, renal impairment or failure,
             alcohol (ETOH) or drug abuse, GI complaints.

          -  Previous investigational therapy within 28 days or 5 half lives
Clinical trial NCT02066415 (phase 2, status: completed)
Conditions: treatment for prevention of chronic migraine
ICD codes: Z01.12, Z92.89, Z75.2, M27.59, Z53.9, Z91.19, M27.51
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of at least 5 attacks of migraine without aura and/or migraine with visual
             sensory, speech and/or language, retinal or brainstem aura.

          -  History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by
             the subject as migraine day.

          -  ≥ 4 distinct headache episodes, each lasting ≥ 4 hours OR if shorter, associated with
             use of a triptan or ergot-derivative on the same calendar day based on the eDiary
             calculations.

          -  Demonstrated at least 80% compliance with the eDiary.

        Exclusion Criteria:

          -  History of cluster headache or hemiplegic migraine headache

          -  Unable to differentiate migraine from other headaches

          -  Failed > 3 medication categories due to lack of efficacy for prophylactic treatment of
             migraine .

          -  Received botulinum toxinin head or neck region within 4 months prior to screening.

          -  Used a prohibited migraine prophylactic medication, device or procedure within 2
             months prior to the start of the baseline phase
Clinical trial NCT02068352 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: opa-15406, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects 10-70 years of age

          -  Diagnosis of atopic dermatitis (AD)

          -  History of AD for at least 3 years

          -  AD affecting greater than or equal to 5% and less than or equal to 40% of total Body
             Surface Area (BSA) at Baseline

          -  Investigator's Global Assessment of Disease Severity score of 2 (mild) or 3 (moderate)
             in the selected treatment area(s)

        Exclusion Criteria:

          -  Contact or atopic dermatitis flare within 28 days of the Baseline (Day 1) visit.

          -  Concurrent diseases/conditions and history of other diseases/conditions in the
             selected treatment areas(s) that may have an impact on the study assessments.
Clinical trial NCT02068599 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: tv-45070, placebo
SMILES: FC(F)(F)C1=CC=C(CN2C(=O)[C@@]3(COC4=C3C=C3OCOC3=C4)C3=CC=CC=C23)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is between 40 and 85 years of age, Patient has primary OA in a single knee
             (target knee) confirmed by American College of Rheumatology criteria.

          -  For patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics
             at the time of the screening visit,

          -  Patient has visual analog scale (VAS) pain scores with acceptable ranges as determined
             by the investigator during screening

          -  Except for OA, patient is judged by the investigator to be medically healthy and able
             to participate in the study.

          -  Other criteria apply, please contact the investigator for additional information

        Exclusion Criteria:

          -  Patient has secondary or inflammatory arthritis of the knee such as psoriasis,
             rheumatoid arthritis (RA), gout, other primary bone disease, or acute trauma.

          -  Patient has symptomatic chondrocalcinosis

          -  Patient has a history of fibromyalgia.

          -  Patient has any painful or disabling conditions that in the opinion of the
             investigator may confound assessment of pain scoring.

          -  Patient has uncontrolled cardiac, renal, hepatic or other systemic disorders that in
             the opinion of the investigator may jeopardize the patient.

          -  Patient has significant edema or skin disorder (including sores, rashes, or ulcers) at
             the target knee and surrounding area.

          -  Patient has a history of total or partial knee replacement in either leg.

          -  Patient had a major reconstructive knee surgery or arthroscopy of the target knee
             within 6 months before the screening visit.

          -  Patient is unable or unwilling to discontinue opioid and/or other prescription
             analgesics for control of OA pain.

          -  Patient is intolerant to study drug, its excipients, and/or acetaminophen.

          -  Patient uses any over the counter oral medications such as glucosamine or chondroitin
             sulfate products, unless the patient has been receiving the medication for ≥3 months
             at the time of the screening visit and maintains the medication as stable therapy for
             the duration of the study.

          -  Other criteria apply, please contact the investigator for additional information
Clinical trial NCT02070120 (phase 2, status: active, not recruiting)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: mitomycin c
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or
             Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables

          -  Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis

          -  Aged 16 or over

          -  Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit
             of Normal (ULN)

          -  Negative pregnancy test for women of child-bearing potential

        Exclusion Criteria:

          -  Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant
             carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per
             year since initial diagnosis or in the past five years, whichever is shorter

          -  Any history of histologically confirmed non-TCC bladder cancer

          -  Trial entry recurrence identified within 11.5 months of the date of the original
             diagnosis

          -  Any prior treatment of the trial entry recurrence (including biopsy)

          -  Previous MMC chemotherapy other than a single instillation at diagnostic surgery

          -  Known allergy to MMC

          -  Carcinoma involving the prostatic urethra or upper urinary tract (participants should
             have had imaging of the upper urinary tract within 2 years prior to randomisation)

          -  Known or suspected reduced bladder capacity (<100ml)

          -  Significant bleeding disorder

          -  Female patients who are breast-feeding or are of childbearing potential and unwilling
             or unable to use adequate non-hormonal contraception. Male patients should also use
             contraception if sexually active.

          -  Active or intractable urinary tract infection

          -  Urethral stricture or anything impeding the insertion of a catheter

          -  Large narrow neck diverticula

          -  Significant urinary incontinence

          -  Any other conditions that in the Principal Investigator's opinion would contraindicate
             protocol treatment

          -  Unable or unwilling to comply with study procedures or follow up schedule
Clinical trial NCT02070744 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-661, ivacaftor, placebo matched to vx-661, placebo matched to ivacaftor
SMILES: CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Homozygous for the F508del CFTR mutation

          -  FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height

          -  Stable CF disease as judged by the investigator

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             participant

          -  Pregnant and nursing females: Females of childbearing potential must have a negative
             pregnancy test at screening and Day 1 of the PC Phase and Day -7 or Day 1 of the OLE
             Phase (whichever was applicable)

          -  Sexually active participants of reproductive potential who are not willing to follow
             the contraception requirements

          -  The participant or a close relative of the participant is the investigator or sub
             investigator, research assistant, pharmacist, study coordinator, or other staff
             directly involved with the conduct of the study.
Clinical trial NCT02070991 (phase 2, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: macitentan, placebo
SMILES: CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males and Females >=18 years of age

          2. Subjects with combined pre-and post-capillary Pulmonary Hypertension (CpcPH) due to
             left ventricular dysfunction (subset of WHO groups 2.1 and 2.2)

          3. Optimized diuretic therapy

        Exclusion Criteria:

          1. Types of Pulmonary Hypertension other than WHO groups 2.1 and 2.2 (Nice
             classification)

          2. Administration of PAH-specific therapy (i.e., Endothelin receptor antagonists (ERAs),
             Prostanoids, Phosphodiesterase 5 (PDE-5) inhibitors, guanylate cyclase stimulators)
Clinical trial NCT02072161 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: etc-1002, placebo, statin therapy
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Fasting, calculated mean LDL-C ≥130 mg/dL and ≤220 mg/dL

          -  Fasting mean TG level ≤400 mg/dL

          -  Stable statin therapy for at least 3 months prior to screening: atorvastatin (10 or 20
             mg daily), simvastatin (5, 10 or 20 mg daily), rosuvastatin (5 or 10 mg daily), or
             pravastatin (10, 20 or 40 mg daily)

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease within 12 months of screening

          -  Current muscle-related symptoms that may be due to ongoing statin therapy or a history
             of certain lab abnormalities that occurred during statin therapy and resolved when
             statin therapy was discontinued

          -  Type 1 diabetes or uncontrolled type 2 diabetes

          -  Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening

          -  History of chronic musculoskeletal symptoms such as fibromyalgia

          -  Uncontrolled hypothyroidism

          -  Liver disease or dysfunction

          -  Renal dysfunction or nephritic syndrome

          -  Gastrointestinal conditions or procedures or surgeries

          -  Hematologic or coagulation disorders or low hemoglobin levels

          -  HIV or AIDS

          -  History of malignancy

          -  History of drug or alcohol abuse within 2 years

          -  Use of experimental or investigational drugs within 30 days of screening

          -  Use of ETC-1002 in a previous clinical study
Clinical trial NCT02077374 (phase 2, status: completed)
Conditions: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease
ICD codes: K75.81, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: idn-6556
SMILES: C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects of minimum adult legal age (according to local laws for
             signing the informed consent document), able to provide written informed consent, and
             understand and comply with the requirements of the study

          -  Diagnosis of non-alcoholic fatty liver disease (NAFLD) as evidenced by imaging or
             other diagnostic assessments

          -  Alanine aminotransferase (ALT) levels ≥1.5 x ULN on at least two occasions, seven or
             more days apart, during the Screening period

          -  alpha-fetoprotein (AFP) ≤ 100 ng/mL

          -  Hemoglobin ≥10 g/dL, a platelet count ≥ 100 x 10^9/L, and a white blood cell count ≥
             3.0 x 10^9/L

          -  If on metformin, sulfonylureas, statins, or fibrates, subjects must be on a stable
             dose of these drugs for at least three months prior to Screening and during the study

        Exclusion Criteria:

          -  Known infection with HIV, HCV, or HBV

          -  Decompensated or severe liver disease as evidenced by one or more of the following:

               1. Confirmed cirrhosis or suspicion of cirrhosis

               2. Esophageal varices

               3. Ascites

               4. Suspicion of portal hypertension

               5. Hospitalization for liver disease within 60 days of screening

               6. Bilirubin >2 x ULN, or ALT or AST > 10 x ULN

          -  Inflammatory bowel disease

          -  Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis
             (RA)

          -  Hepatocellular carcinoma (HCC) at entry into the study

          -  History of or active non-liver malignancies other than curatively treated skin cancer
             (basal cell or squamous cell carcinomas)

          -  Significant systemic or major illness other than liver disease, including coronary
             artery disease, cerebrovascular disease, pulmonary disease, renal insufficiency,
             and/or serious psychiatric disease, that, in the opinion of the Investigator would
             preclude the subject from participating in and completing the study

          -  History or presence of alcohol abuse, defined as consumption of more than 210 mL of
             alcohol per week (the equivalent of 14 4-ounce glasses of wine or 14 12-ounce
             cans/bottles of beer or wine coolers), or other substance abuse within the prior two
             years